1,191 material Form 8-K filings that 965 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
IDT Corporation's Board of Directors declared a quarterly cash dividend of $0.07 per share on September 22, 2026. The dividend is payable to stockholders of record as of October 5, 2026, providing a routine cash return to shareholders.
Quarterly cash dividend of $0.07 per share declared September 22, 2026
Nutriband announced that its publicly traded warrants (Nasdaq: NTRBW) will expire automatically under their original terms at 5:00 p.m. Eastern Time on September 30, 2026, and will be delisted after trading ends that day. The company said the expiration has no impact on its common stock, which will continue to trade on Nasdaq as NTRB, and that unexercised warrants will become void.
Warrants (NTRBW) expire at 5:00 p.m. Eastern Time on September 30, 2026
Warrant trading ceases at market close on September 30, 2026, then warrants are removed from Nasdaq listing
Expiration requires no action from warrant holders; common stock (NTRB) is unaffected
FG Nexus Inc. entered into a subscription agreement on September 17, 2026, to buy 1,818,182 shares of common stock of FG Communities, Inc. (FGC) for $10,000,001 in cash, and the purchase closed on September 21, 2026. Several FG Nexus officers and directors, including Chairman and CEO Kyle Cerminara, also hold equity in and serve as officers and directors of FGC, so the board relied on review by an independent special committee and an independent financial advisor.
Purchase of 1,818,182 FGC shares at $5.50 per share, for an aggregate $10,000,001 paid in cash
Agreement dated September 17, 2026; closing occurred September 21, 2026
Kyle Cerminara is Chairman and CEO of FG Nexus and President and Chairman of FGC
Approved by the board after review and recommendation by a special committee of independent directors and an independent financial advisor
Xenetic Biosciences furnished an updated September 2026 investor presentation tied to its pending share exchange with Santersus AG, first announced September 16, 2026. The presentation shows Santersus shareholders expected to own about 85% of the combined company and Xenetic stockholders about 15%, subject to adjustment, with closing expected in the fourth quarter of 2026.
Transaction valuation shown as $120 million for Santersus and $21 million for Xenetic, or $141 million in total, under the Share Exchange Agreement dated September 14, 2026
Closing is expected in the fourth quarter of 2026 and is subject to approval by Xenetic stockholders
The combined company is expected to trade on Nasdaq under the ticker SNTS
On September 22, 2026, Independence Realty Trust (IRT) and related parties signed an amendment to the merger agreement with Centerspace first signed on September 8, 2026. IRT elected an alternative structure for the Company Merger, under which Centerspace would merge into an IRT subsidiary that survives the merger. The filing does not state a deal value or change in consideration, so the amendment's effect on shareholder payments cannot be determined from this document.
Original Merger Agreement with Independence Realty Trust was entered into on September 8, 2026.
On September 22, 2026, IRT Merger Sub joined the agreement by joinder and IRT elected the Alternative Structure for the Company Merger only.
Under the Alternative Structure, IRT Merger Sub survives the Company Merger rather than merging into Centerspace.
The amendment includes a waiver of any representation inaccuracy caused solely by the Alternative Structure and is filed as Exhibit 2.1.
Stoneridge appointed Uwe Brandenburg as Global Vice President, Engineering & Innovation, effective November 2, 2026, under an employment agreement dated September 17, 2026. He will report to CEO Natalia Noblet and lead the company's global engineering organization, and he will serve on the Executive Team.
Annual base salary of €320,000 (about $367,168), with a target bonus of 50% of base salary
One-time special equity grant of $150,000 in time-based Stoneridge shares, vesting ratably over three years
Previously Chief Technology Officer and Senior Vice President, Automotive and Manufacturing at DXC Technology (formerly Luxoft)
IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings, completed a $2 billion offering of 6.375% senior notes maturing March 15, 2034. Proceeds will redeem the issuer's 5.000% notes due 2026, repay part of its revolving credit facility and cover offering fees. The deal refinances existing debt and adds new long-term borrowing, which shareholders may weigh against the company's debt load.
Gross proceeds of $2,000,000,000 from 6.375% senior unsecured notes due March 15, 2034
Proceeds to redeem in full the Senior 5.000% Notes due 2026 and repay part of the revolving credit facility
Interest payable semi-annually on March 15 and September 15, starting March 15, 2027
Issuer may redeem before September 15, 2029 subject to a make-whole premium
Decoy Therapeutics reduced the exercise price of its Series B milestone warrants from $5.91 to $3.25 per share, and the holder exercised 1,184,434 of them in full, bringing approximately $3.85 million in gross proceeds before placement agent fees and expenses; the transaction closed September 23, 2026. In exchange, the company issued new unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately and expiring five years after issuance, which could add meaningful share count dilution for existing holders.
1,184,434 Series B Milestone Warrants exercised in full on September 22, 2026 at a reduced price of $3.25, down from $5.91 per share.
Gross proceeds of approximately $3.85 million, before placement agent fees and other expenses, to be used for working capital and general corporate purposes.
New unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately, expiring five years from issuance.
The company agreed to file a resale registration statement within 15 calendar days of the September 22, 2026 inducement letter.
On September 22, 2026, Independence Realty Trust entered into an amendment to its merger agreement with Centerspace, under which IRT elected an alternative structure for the Company Merger, with Centerspace surviving as a wholly owned subsidiary of IRT. The amendment also includes IRT's waiver of any representation inaccuracy caused solely by the structure change, and the filing does not state any change to the consideration or deal value.
Original Merger Agreement dated September 8, 2026 was amended on September 22, 2026.
IRT Merger Sub was added to the agreement by joinder, and IRT elected the Alternative Structure for the Company Merger only.
Under the change, CSR merges with and into IRT Merger Sub, with IRT Merger Sub surviving.
The transaction remains subject to S-4 and joint proxy filings and votes of CSR and IRT shareholders.
Plug Power said Chief Operating Officer Dean C. Fullerton will resign effective October 23, 2026, to accept a position at another company, having notified the company on September 17, 2026. The filing says the resignation was not due to any disagreement with the company on its operations, policies or practices, and that his duties will move to certain Executive Vice Presidents and Vice Presidents, with Fullerton assisting the transition.
Dean C. Fullerton, Chief Operating Officer, notified the company on September 17, 2026 of his resignation
Resignation takes effect October 23, 2026
Filing states no disagreement with the company on operations, policies or practices
Duties will transfer to certain Executive Vice Presidents and Vice Presidents
TransUnion said Chief Financial Officer Todd Cello will resign effective December 31, 2026, after 29 years with the company, including nine years as CFO. He will serve as a full-time advisor through March 1, 2027, and the company has begun a search for a successor, with an interim CFO expected if no replacement is hired by the transition date. TransUnion also reaffirmed its third quarter and full-year 2026 guidance for revenue, Adjusted EBITDA and Adjusted Diluted Earnings Per Share, and said the departure is not expected to affect operations or long-term financial targets.
Todd Cello resigns as EVP and CFO effective December 31, 2026; he is not leaving over a disagreement with the company
Cello provides transition services through March 1, 2027; the company's search for a successor is underway
Transition agreement dated September 23, 2026 includes salary through March 1, 2027 and a 2026 annual bonus, subject to performance and employment through the transition date, plus COBRA coverage of up to 18 months and outplacement services
TransUnion reaffirmed third quarter and full-year 2026 guidance for revenue, Adjusted EBITDA and Adjusted Diluted EPS
NexMetals reported assay results from drill hole SMD-26-219 at its Selebi Main deposit in Botswana, which returned 7.55 metres grading 6.48% CuEq (2.70% Cu, 1.83% Ni). A visual intercept in hole SMD-26-217 extended the High-Grade Trend by about 100 metres to approximately 1.5 kilometres and showed a third mineralized zone, with assays still pending. The release contains no financial results, and the company said the 2026 Mineral Resource Estimate remains on track for the third quarter of 2026, excluding holes drilled after the September 21 cut-off, including SMD-26-217.
SMD-26-219 returned 7.55 metres grading 6.48% CuEq in the Lower Zone, between 1,909.20 and 1,916.75 metres.
SMD-26-217 extended the High-Grade Trend by about 100 metres and intersected a combined 38.65 metres of mineralization across three zones; assays are pending.
The 2026 Mineral Resource Estimate remains on track for completion in the third quarter of 2026; holes drilled after September 21, including SMD-26-217, are excluded.
Sun Communities closed the sale of its UK business, Park Holidays, to Panther Bidco Limited, an affiliate of Aermont Capital, on September 22, 2026. The company received net cash proceeds of approximately $1.03 billion and says it expects to use them primarily for share repurchases, debt repayment and general corporate purposes. The company previously recorded a $1.1 billion valuation allowance charge on the UK business in the second quarter of 2026, and it will update its full-year 2026 outlook on its third quarter earnings call.
Closed on September 22, 2026; buyer Panther Bidco Limited is an affiliate of Aermont Capital
Net cash proceeds of approximately $1.03 billion after closing and transaction costs
Valuation allowance charge of $1.1 billion recorded in the three months ended June 30, 2026
Year-to-date through September 21, 2026, the company repurchased about 3.5 million shares for about $425 million
Wells Fargo said on September 23, 2026 that Scott E. Powell will become its Chief Risk Officer effective January 15, 2027. After that date he will no longer serve as the company's Chief Operating Officer. The filing does not describe the reasons for the change or any compensation terms.
Scott E. Powell appointed Chief Risk Officer, effective January 15, 2027
Powell will no longer serve as Chief Operating Officer after that date
Announced September 23, 2026 in an SEC Form 8-K under Item 5.02
QuidelOrtho entered into Amendment No. 1 to its credit agreement dated August 21, 2025, with Bank of America as administrative agent. The amendment resets the maximum leverage and minimum interest coverage covenant levels through the fiscal quarter ending September 30, 2029, and sets new pricing and commitment fees during that period. The filing describes added restrictions on the financial covenants, so shareholders gain covenant room but face tighter terms in the interim.
Amendment dated September 23, 2026 to the credit agreement originally dated August 21, 2025
Maximum Consolidated Leverage Ratio set at 5.50 to 1.00 for quarters through July 2, 2028, stepping down to 4.25 to 1.00 on or after September 30, 2029
Minimum Consolidated Interest Coverage Ratio set at 2.25 to 1.00, rising to 3.00 to 1.00 on or after September 30, 2029
Initial Term SOFR margin of 2.50% per annum for the Term Loan A facilities and revolver until the compliance certificate for the quarter ending September 28, 2026 is received; term loan B interest unchanged
Flotek Industries entered into a Credit Agreement on September 23, 2026, with initial term loans of $75.0 million, secured by substantially all company and subsidiary guarantor assets. The loan refinanced the $40 million PWRTEK Note, which had been guaranteed by Flotek, and matures September 23, 2031. Part of the lender group is an affiliate of ProFrac's founders, a related party, and the Audit Committee approved the transaction.
Initial term loans of $75.0 million, with up to $15.0 million more delayed-draw available through June 30, 2027 and up to $30.0 million more subject to Required Lender consent through March 31, 2028
Interest at Term SOFR with a 2.50% floor plus a 6.50% margin; maturity September 23, 2031
PC Energy Credit I LLC, an affiliate of ProFrac's founders, exchanged $12.5 million of PWRTEK Note obligations for initial term loans
Asset-based loan with Amerisource extended to October 31, 2027, with the PWRTEK Note terminated and its liens released
Five Below's board increased its size from nine to ten directors and elected Scott Settersten, former Chief Financial Officer of Ulta Beauty, effective September 21, 2026, with a seat on the Audit Committee. The filing says the board considers him independent, and he received an initial grant of 545 restricted stock units that vests at the next annual shareholder meeting.
Scott Settersten elected September 21, 2026; board expanded from nine to ten directors
Served as CFO of Ulta Beauty from 2012 until retiring in March 2024; previously 15 years at PricewaterhouseCoopers LLP
Initial grant of 545 restricted stock units; term runs until the 2027 annual shareholder meeting
Alcoa's subsidiaries completed a $2.6 billion private sale of senior notes due 2034 and 2036, with proceeds and cash on hand intended to fund the approximately $3.1 billion cash portion of the proposed South32 bauxite, alumina and aluminum smelter acquisition. The notes must be redeemed at 100% of principal plus accrued interest if the acquisition is not completed by the Special Mandatory Redemption End Date, which is at least June 29, 2027, and the company terminated its 364-day bridge loan commitments for the deal.
$1.5 billion of 6.625% senior notes due 2034 issued by Alumina Pty Ltd and $1.1 billion of 6.875% senior notes due 2036 issued by Alcoa Nederland Holding B.V.
Proceeds plus cash on hand are intended to fund the approximately $3.1 billion cash portion of the South32 acquisition and related fees and expenses.
If the acquisition is not completed by June 29, 2027, or a later date under the Deed, the notes must be redeemed at 100% of principal plus accrued interest.
Concurrently with the notes closing, Alcoa terminated all remaining commitments under its 364-day senior unsecured bridge term loan facility.
SCWorx received a Nasdaq Hearings Panel decision to delist its common stock, which has been suspended from Nasdaq since April 14, 2026, and now trades on the OTCQB. The company says a September 16, 2026 private placement cured its publicly held shares deficiency and has asked the Panel to reconsider, but the Panel has not yet acted, and the outcome is uncertain for shareholders.
Nasdaq Hearings Panel decided on September 17, 2026 to delist the common stock; the company requested reconsideration on September 18, 2026.
The company says the private placement and related share issuances give it more than 500,000 publicly held shares, meeting the Publicly Held Shares Rule.
To regain Bid Price Rule compliance, the stock must close at or above $1.00 for 10 consecutive trading days on or before October 5, 2026.
If all purchasers terminate, the company would return an aggregate of $938,000 and cancel 350,000 shares and warrants; the deadline for termination notices is October 15, 2026.
Myseum.AI said on September 23, 2026 that it intends to apply to tokenize its Nasdaq-listed common stock through one or more qualified digital-asset securities platforms. The company says tokenized shares would represent its actual registered common stock and preserve shareholder rights, and that existing shareholders need take no action, but the filing states there is no assurance the application will be accepted or that tokenized trading will become available.
Announced September 23, 2026 that it intends to apply to tokenize its common stock
Tokenized shares would be designed to represent actual registered common stock, not synthetic exposure, and preserve economic and voting rights
Common stock will continue to trade on the Nasdaq Capital Market under the symbol MYSE; no shareholder action is required
Filing states there can be no assurance the application will be accepted or that tokenized trading will become available
Unity Bancorp said CEO James A. Hughes will retire effective March 31, 2027, and President George Boyan will become CEO effective April 1, 2027, under a planned succession process. Hughes will remain on the boards of the Company and Unity Bank. The company also amended Hughes' retirement plan, raising his benefit percentage from 60% to 65%, which will produce a one-time pre-tax expense of $769 thousand in the quarter ending September 30, 2026.
James A. Hughes retires as CEO effective March 31, 2027, and will continue as a director of the Company and Unity Bank
George Boyan, President since January 1, 2026, becomes CEO effective April 1, 2027
SERP amendment raises Hughes' retirement benefit from 60% to 65% of the compensation measure, with a one-time pre-tax expense of $769 thousand in the quarter ending September 30, 2026
FMC closed the sale of 30,319,166 common shares to Tessenderlo Group NV at $13.30 per share, for an aggregate purchase price of $403,244,907.80, on September 23, 2026. Tessenderlo now owns approximately 20.0% of FMC's outstanding shares and gains a board nomination right, a board observer seat and preemptive rights. The filing also sets a 36-month lock-up and standstill limits, which shape how much influence and share-count dilution existing shareholders may face.
Tessenderlo bought 30,319,166 shares at $13.30 per share, for $403,244,907.80 in total.
Tessenderlo owns approximately 20.0% of FMC's outstanding common stock after the closing.
The Investor Agreement lets Tessenderlo nominate an independent director; Luc Tack, Tessenderlo's chief executive, has been nominated.
Tessenderlo is subject to a 36-month lock-up and customary standstill restrictions while it holds FMC shares.
On September 21, 2026, Bath & Body Works' compensation committee granted CEO Daniel Heaf a performance stock unit award with a target value of $10 million, equal to 591,366 shares. The award vests only if the average closing stock price over any 60 consecutive trading days reaches $40, $60, $80 or $100 during a four-year performance period, tying a large part of his pay to share price gains.
Target value of $10 million, equal to 591,366 shares of common stock, granted September 21, 2026 to CEO Daniel Heaf
Payout ranges from 75% to 200% of target at stock price goals of $40, $60, $80 and $100 over a four-year performance period
Earned units vest on the fourth anniversary of the grant date, generally subject to continued employment; earned amount is halved if total shareholder return ranks below the 55th percentile of the S&P 1500 Consumer Discretionary Distributio
Solaris Energy Infrastructure's subsidiary agreed on September 22, 2026 to sell $1.25 billion of 7.000% senior notes maturing April 1, 2032, in a private placement to initial purchasers led by MUFG Securities Americas. The offering was upsized from an original $1.0 billion, and the company expects about $1,227.2 million in net proceeds for general corporate purposes, growth capital expenditures and offering fees, with closing expected October 1, 2026.
Principal amount: $1.25 billion of 7.000% senior notes due April 1, 2032, issued at par, upsized from $1.0 billion
Expected net proceeds: approximately $1,227.2 million after the initial purchasers' discount and estimated offering expenses
Expected closing: October 1, 2026, subject to customary closing conditions
Use of proceeds: general corporate purposes, growth capital expenditures and offering fees and expenses
Jazz Pharmaceuticals' subsidiary Jazz Financing Lux entered into Amendment No. 4 to its credit agreement on September 23, 2026, extending the maturity of the $1.9 billion Tranche B-2 dollar term loan from May 5, 2028 to May 5, 2033 and lowering its interest margin. The filing does not include new earnings, guidance, or changes to operations, so the effect on shareholders depends on the lower borrowing cost and longer repayment schedule.
Maturity extended from May 5, 2028 to May 5, 2033 for the Tranche B-3 dollar term loans
Applicable margin cut 50 basis points to 1.75% for Term SOFR borrowings and 0.75% for prime rate borrowings, with a 0.50% Term SOFR floor
Principal outstanding of $1,895,000,000 before and after the amendment; Jazz Lux also borrowed $273,310,355.18 in additional term loans to repay non-converted loans
Quarterly amortization of 0.25% of initial principal, with the remaining balance due May 5, 2033
HealthStream's Compensation Committee approved special grants of time-based and performance-based restricted share units to its named executive officers on September 18, 2026, under its shareholder-approved 2022 Omnibus Incentive Plan. The grants are meant to encourage future performance and retention, and they add to the equity compensation of these officers.
Four named executive officers (Robert A. Frist, Jr., Michael M. Collier, Trisha L. Coady, Kevin P. O'Hara) each received 15,395 time-based RSUs with a grant date fair value of $450,000, plus 5,132 performance-based RSUs valued at $150,000 e
Scott A. Roberts received 12,316 time-based RSUs valued at $360,000 and 4,105 performance-based RSUs valued at $120,000.
Time-based RSUs vest in equal annual 25% installments over four years from the grant date.
Performance-based RSUs vest in 25% increments tied to annual targets for 2027 through 2030, to be set by the Committee.
Covista Inc. entered into Amendment No. 6 to its credit agreement on September 18, 2026, repricing all $510 million of outstanding term loans. The Term SOFR margin falls from 2.25% to 2.00%, and the base rate margin falls from 1.25% to 1.00%, which lowers the interest rate on the loans. The filing states that the other terms of the credit agreement were not materially changed.
Amendment No. 6, dated September 18, 2026, repriced all $510 million of term loans, with Morgan Stanley Senior Funding, Inc. as administrative agent.
Term SOFR margin reduced from 2.25% to 2.00%; base rate margin reduced from 1.25% to 1.00%.
A 1.00% soft call applies to certain repricings or prepayments occurring within six months after the September 18, 2026 effective date.
Other material terms are unchanged; the full amended agreement is filed as Exhibit 10.1.
Sarepta Therapeutics entered a settlement agreement with REGENXBIO, the Trustees of the University of Pennsylvania and Catalent to resolve pending patent infringement litigation and an related appeal over several patents. Sarepta will pay REGENXBIO a lump sum of $39.0 million, an amount it had already recorded as a litigation contingency charge in the second quarter of 2026. The settlement releases Sarepta from past infringement claims and includes covenants not to sue for ELEVIDYS and other AAVrh74-based products, which removes a source of legal uncertainty for shareholders.
Sarepta will pay REGENXBIO a $39.0 million lump sum within ten days of the September 23, 2026 Effective Date.
The $39.0 million matches a litigation contingency charge recorded in the three and six months ended June 30, 2026.
REGENXBIO and UPenn released claims up to the Effective Date and agreed not to sue over ELEVIDYS and other AAVrh74-based products under the UPenn Patents.
The Litigations will be dismissed with prejudice, and the settlement includes no admission of liability.
Gossamer Bio said it submitted a New Drug Application to the FDA in September 2026 for seralutinib to treat pulmonary arterial hypertension, its first NDA. The application relies on the Phase 3 PROSERA study as one adequate and well-controlled investigation, supported by the Phase 2 TORREY study. The FDA has not yet decided whether to accept the application for filing, which the company expects could happen later this year.
NDA for seralutinib in PAH submitted to the FDA in September 2026, the company's first NDA
Submission follows a Pre-NDA Type B meeting with the FDA in June 2026 and the FDA's written meeting minutes
FDA will decide whether to accept the NDA for filing after its initial review, which the company anticipates could occur later this year
REGENXBIO and the University of Pennsylvania agreed to settle patent infringement litigation with Sarepta Therapeutics and Catalent over Sarepta's ELEVIDYS gene therapy. Sarepta will pay REGENXBIO $39.0 million within 10 days of the settlement's effective date, and the parties will end the ongoing patent litigation.
Sarepta will pay $39.0 million to REGENXBIO within 10 days of the settlement's effective date.
The settlement covers U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274, related to SRP-9001 (ELEVIDYS).
REGENXBIO and UPenn release current infringement claims and agree to a covenant not to sue for future claims on AAVrh74-based Sarepta gene therapy products.
The full agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Flywire Corporation's board appointed Sabrina Farmer as a Class II director on September 22, 2026, increasing the board from nine to ten members. She also joined the Nominating and Corporate Governance Committee, and the filing describes her as independent under Nasdaq rules. The filing reports no financial results, and the board change itself does not include financial figures beyond her director pay.
Board appointed Sabrina Farmer on September 22, 2026; her initial term expires at the 2029 annual meeting.
Board size increased from nine to ten directors.
Annual cash retainer of $35,000 for board service plus $4,000 for Nominating and Corporate Governance Committee service.
Initial restricted stock unit award with a fair market value of $350,000, vesting in three equal annual installments, and an annual award of $175,000 tied to annual meetings.
Stitch Fix reported fourth quarter and full fiscal 2026 results, with revenue up 4.2% in the quarter and 6.4% for the year, and a narrower net loss than a year earlier. The company expects fiscal 2027 revenue of $1.310 billion to $1.360 billion, a decline of 2.8% to growth of 0.9%, citing a more challenging consumer environment and a lower active client base, which weighs on shareholder expectations for growth.
Q4 fiscal 2026 net revenue was $324.4 million, up 4.2% year-over-year, with a net loss of $2.1 million versus $8.6 million a year earlier.
Full fiscal 2026 net revenue was $1.35 billion, up 6.4%, with a net loss of $12.6 million versus $28.7 million; gross margin was 43.7%, down 70 basis points.
Fiscal 2027 net revenue outlook is $1.310 billion to $1.360 billion, or (2.8)% to 0.9% year-over-year; Q1 fiscal 2027 outlook is $323 million to $328 million, or (5.6)% to (4.1)%.
Active clients were 2.277 million at August 1, 2026, down 1.4% year-over-year; the company cited shipment timing and an August post-checkout offer flow change that reduced Fix volume in Q1.
Apogee Enterprises said it completed its acquisition of GroGlass, a Latvian glass coatings business, on September 18, 2026. The deal values GroGlass at approximately €62.5 million on a cash-free, debt-free basis, plus contingent consideration of up to €10 million tied to financial targets over three years after closing.
Acquisition closed September 18, 2026, through subsidiary Tiger MergeCo SIA
Valued at approximately €62.5 million cash-free, debt-free; earnout capped at €10 million over three years
Funded with available cash and borrowings under the existing revolving credit facility
Press release puts total value at up to approximately $71.8 million at current exchange rates, including earnout
Ondas Inc. completed acquisitions of CaribouLabs, Insignito Solutions and Ottopia Technologies on September 23, 2026, for aggregate consideration of $56 million payable in cash or common stock, with up to $32 million in potential earnouts through 2028. The company also filed a prospectus covering resale by certain stockholders of 7,822,077 shares issued in the acquisitions and a prior World View acquisition, and granted inducement equity awards to 37 new employees.
Aggregate consideration of $56 million; potential earnout of up to $32 million through 2028, payable in cash or stock.
Filing covers resale of 7,822,077 shares, including 7,821,445 shares issued on September 23, 2026 for the three acquisitions and 632 shares issued April 1, 2026 for the World View Enterprises acquisition.
Inducement grants of 2,979,063 RSUs and options on 80,000 shares, at an exercise price of $7.72, were approved for 37 newly hired employees.
Greenland Technologies Holding Corporation received a Nasdaq letter on September 22, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement. The company's Class A ordinary shares closed at $1.00 or above for 10 consecutive business days from September 8 through September 21, 2026, and Nasdaq has closed the matter. For shareholders, this removes the risk of delisting over the bid price issue.
Nasdaq notified the company on March 12, 2026 that its Class A ordinary shares had closed below $1.00 for 30 consecutive business days
On September 10, 2026, Nasdaq granted an additional 180-day period, to March 8, 2027, to regain compliance
On September 22, 2026, Nasdaq confirmed compliance after 10 consecutive business days at or above $1.00, from September 8 through September 21, 2026
Pilgrim's Pride Corporation and its subsidiary Pilgrim's Europe Finance PLC completed a private sale of €500 million of 4.750% senior notes due January 23, 2034, on September 23, 2026. The company said it will use the net proceeds for general corporate purposes, including the consideration for its recently announced acquisition of Walkers Deli & Sausage Company, which adds debt that shareholders should weigh against the deal.
Principal amount: €500 million of 4.750% senior notes, issued by Pilgrim's Pride and Pilgrim's Europe Finance PLC as co-issuers
Interest is payable annually in arrears each January 23, starting January 23, 2027; notes mature January 23, 2034
Proceeds are intended for general corporate purposes, including funding the Walkers Acquisition consideration and related costs
Notes were sold to qualified institutional buyers under Rule 144A and to certain non-US persons under Regulation S; Citibank, N.A., London Branch is trustee
Ampco-Pittsburgh posted a September 2026 investor presentation to its website, to be used at the Sidoti conference on September 23, 2026. The deck reports 2025 revenue of $434 million, 2025 adjusted EBITDA of $29.2 million and a net debt to EBITDA ratio of about 3.0x, and sets a target of double-digit adjusted EBITDA margins, which it describes as a future goal rather than a current result.
2025 net sales were $434 million, with adjusted EBITDA of $29.2 million, a 6.7% margin.
Management expects about $7 million to $8 million of annual EBITDA improvement from portfolio actions, including the exit of a U.K. cast roll facility and the divestiture of a non-core steel distribution business.
The company expects average organic revenue growth of 10% to 12% over the next three years, and cites approval of about $9 million in U.S. Navy funding for its Buffalo pump facility.
The presentation notes ongoing insolvency proceedings at Union Electric Steel UK Limited, which the company says could affect its financial condition.
Patriot National Bancorp agreed on September 18, 2026 to issue and sell $10.0 million of subordinated notes to qualified institutional buyers. The company says the notes are intended to qualify as Tier 2 regulatory capital, and the filing does not say how the proceeds will be used.
Principal amount: $10.0 million of 8.5% Fixed to Floating Rate Subordinated Notes due 2036, maturing September 30, 2036
Fixed 8.5% annual rate, paid semi-annually until September 30, 2031; afterward resets quarterly to three-month SOFR plus 416 basis points
Company may redeem on or after September 30, 2031, or earlier in certain events, subject to regulatory approval where required
Notes are unsecured, junior to senior indebtedness, not convertible, and not guaranteed by subsidiaries; placement agent was Performance Trust Capital Partners, LLC
Paychex reported first-quarter fiscal 2027 results for the three months ended August 31, 2026, with total revenue up 6% to $1.6 billion and diluted earnings per share up 14% to $1.21. The company raised its fiscal 2027 outlook for PEO and Insurance Solutions revenue growth to 7% to 8% and left most other guidance unchanged, including adjusted diluted EPS growth of 7% to 9%.
Total revenue rose 6% to $1.6 billion; operating income rose 14% to $619.2 million.
Adjusted diluted EPS rose 10% to $1.34; GAAP diluted EPS rose 14% to $1.21.
PEO and Insurance Solutions revenue growth outlook raised to 7% to 8% from 6% to 7%; interest on funds held for clients outlook raised to $200 million to $210 million.
Paid dividends of $1.19 per share totaling $424.1 million in the quarter; cash flow from operations was $413.5 million, down from $718.4 million a year earlier.
Cintas reported first-quarter fiscal 2027 revenue of $3.01 billion, up 10.9%, and diluted EPS of $1.36, up 13.3% from a year earlier. The company raised its full-year revenue and adjusted EPS guidance, though the results include $14.4 million of transaction expenses tied to the proposed UniFirst acquisition, which is still under review by the U.S. Federal Trade Commission.
First-quarter revenue of $3.01 billion, up 10.9%; organic revenue growth of 8.9%
Diluted EPS of $1.36 vs. $1.20 a year earlier; adjusted diluted EPS of $1.39, up 15.8%
Fiscal 2027 revenue guidance raised to $12.15 billion to $12.27 billion; adjusted diluted EPS guidance raised to $5.45 to $5.54
UniFirst transaction expenses of $14.4 million; closing expected before the end of calendar 2026
Edgewell Personal Care said LaTanya Langley will become Chief Administrative and Legal Officer and Corporate Secretary effective October 1, 2026, and will leave her Chief People Officer role on the same date. The filing states there are no changes to her compensation tied to these role changes.
Role change effective October 1, 2026, determined by the company on September 17, 2026
Langley will no longer serve as Chief People Officer as of October 1, 2026
No change to Langley's compensation in connection with the role changes
Greenpro Capital Corp. agreed on September 18, 2026 to sell six subsidiaries, the F&A Entities, which provide corporate advisory and company-secretarial services in Hong Kong and China, to Chen Yanhong, a director of several of them, for aggregate cash of HK$3,500,000 (approximately US$446,486). The deal is expected to close before the end of September 2026, and at closing intercompany balances between those entities and the rest of the group will be waived without further consideration.
Sale of six F&A Entities to Chen Yanhong for HK$3,500,000 (approximately US$446,486), under an agreement dated September 18, 2026
Audit committee approved the transaction on September 8, 2026; board approved it on September 11, 2026
Expected closing before the end of September 2026, subject to closing conditions
Greenpro Trust Limited agreed to invest $12,500,000 in subsidiary GVCL for 5% of its equity, valuing GVCL at $250,000,000; funds received August 25, 2026
Corcept Therapeutics said Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, and Justin Gunn will succeed him. Maduck will stay on as a consultant under an agreement paying $57,000 per month, and the company said he did not resign because of any disagreement with the company. The filing does not include financial results or guidance changes, so the direct effect on shareholders is limited to the leadership change.
Sean Maduck notified the board on September 22, 2026 of his decision to resign effective October 1, 2026.
Maduck's consulting agreement runs through September 30, 2027, with a cash fee of $57,000 per month, and his outstanding stock options continue to vest.
Justin Gunn joined Corcept in July 2024 as Vice President of Sales and Commercial Learning for the Oncology division and will report to CEO Joseph K. Belanoff, M.D.
MeiraGTx appointed Alan M. Sebulsky to its Board of Directors as a Class I director, effective September 23, 2026, and named him to the Science and Technology Committee. Mr. Sebulsky previously spent about 14 years as a Partner and Portfolio Manager at Adage Capital Management, where he managed a biopharmaceutical portfolio, and the company said he brings healthcare investment experience as it transitions to a commercial company.
Board appointment effective September 23, 2026; term runs to the 2028 annual meeting of shareholders
Mr. Sebulsky joins the Science and Technology Committee
Previously Partner and Portfolio Manager at Adage Capital Management from July 2012 to April 2026; Managing Member of Apothecary Capital LLC since April 2026
Company states there are no related party transactions with Mr. Sebulsky
Beyond Meat entered into privately negotiated exchange agreements to swap about $15.0 million of its 0% convertible notes due 2027 for common stock at 96% of face value. The company will issue 1,097,444 shares initially, with a possible additional true-up of up to 848,265 shares, which would dilute existing shareholders.
About $15.0 million principal of 2027 convertible notes to be exchanged at 96% of face value.
Initial settlement of 1,097,444 shares on or about September 23, 2026.
Final true-up settlement, if any, on or about September 28, 2026, for up to 848,265 additional shares.
Share count depends on a VWAP calculation over three trading days starting September 23, 2026, with a $7.4009 floor price.
McDonald's unveiled its McDonald's > NEXT strategy and multi-year financial targets, running through 2030, in a press release tied to its Investor Day on September 23, 2026. The company plans about $8.5 billion in total NEXT partnering support for franchisees through 2036, including about $5 billion through 2030, and says the targets are meant to drive growth and efficiency for shareholders.
Targets 1.5 percentage points of share gains in both chicken and beverage by 2030 while maintaining beef market share leadership
Targets an operating margin in the low-to-mid 50% range by 2030 and about 250 basis points of gross restaurant-level efficiency gains
Plans about $8.5 billion in total NEXT partnering support through 2036, including about $5 billion through 2030, via rent relief and capital support
Expects about $3 billion of annual baseline capital expenditures from 2027 through 2030, plus $1.5 billion to $2 billion of cumulative capital partnering support
CytoSorbents said it regained compliance with Nasdaq's $1.00 minimum bid price requirement after its closing bid price was at or above $1.00 for 10 consecutive trading sessions ending September 21, 2026, and Nasdaq closed that matter on September 22, 2026. The company still has not met Nasdaq's $35 million minimum market value of listed securities requirement, which it must meet by December 28, 2026, or it will receive a delisting notice, and the company states there is no assurance it will maintain its Nasdaq listing.
Nasdaq notified the company on September 22, 2026 that it regained compliance with the $1.00 minimum bid price requirement and closed the matter.
The company must have listed securities worth at least $35 million for 10 consecutive business days by December 28, 2026 to regain compliance with the market value requirement.
The company is evaluating actions and may consider increasing stockholders' equity to at least $2.5 million.
If the company does not regain compliance by December 28, 2026, it will receive a delisting notice and may appeal.
Astrana Health said social engineering attacks, in which threat actors impersonated company personnel and spoofed its main phone number, led to unauthorized activity in its environment. The company has determined the incident is material and believes certain private or confidential information was accessed or acquired, but the full scope remains under investigation. The company currently does not expect a material effect on its financial condition and results of operations, though it cannot yet estimate the full impact.
Company determined the incident is material as of September 22, 2026, citing the potential confidential and sensitive nature of the data involved.
Threat actors impersonated Company personnel and spoofed the main corporate telephone number to contact employees seeking unauthorized system access.
Company engaged a third-party forensics firm, notified law enforcement, and is notifying state and federal regulators and payer partners.
Company maintains cybersecurity insurance but says coverage may not be sufficient to cover all losses.
Cracker Barrel reported fourth-quarter fiscal 2026 revenue of $849.3 million, down 2.2% from a year earlier, while GAAP net income rose to $12.2 million from $6.8 million. For the full year, GAAP net income fell to $31.7 million from $46.4 million, and the company gave fiscal 2027 revenue and adjusted EBITDA outlooks of $3.325 billion to $3.4 billion and $180 million to $200 million.
Q4 GAAP diluted EPS was $0.54 versus $0.30; adjusted diluted EPS was $0.99 versus $0.74
Q4 adjusted EBITDA was $62.1 million versus $55.7 million, including about $9.1 million from tariff refunds, net of investments
Full-year total debt fell to $337.2 million from $484.6 million; a $150 million convertible note matured in June 2026
Quarterly dividend of $0.25 per share is payable November 12, 2026, to holders of record as of October 16, 2026
Armata Pharmaceuticals said it received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 program for AP-SA02, its lead clinical candidate. The company said this is the first DoW funding specifically for Phase 3 execution, and it lifts cumulative non-dilutive DoW support for the program to approximately $32.4 million, which may reduce the need to raise capital through share sales.
Armata received $3.7 million in additional non-dilutive funds from the U.S. Department of War, announced September 23, 2026.
The award is administered through the Medical Technology Enterprise Consortium and funded by the Defense Health Agency and Joint Warfighter Medical Research Program.
Cumulative non-dilutive DoW funding under the award is approximately $32.4 million, following $28.7 million previously provided.
The company plans to start a Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.